Research & Development
Breast Cancer: Page 2
Exact Sciences to present study data on its precision oncology portfolio at SABCS
The firm announced that it will be sharing the data in 10 abstracts and three presentations, highlighting its Oncotype Dx Breast Recurrence Score and Oncomap ExTra tests, as well as offering a look at its tumor-naïve MRD approach.
December 7, 2022
Agendia to present abstracts on gene expression profiling tests at 2022 San Antonio Breast Cancer Symposium
Six studies focus on the impact of Agendia's MammaPrint and BluePrint tests and their ability to unveil the underlying biology of a breast cancer patient’s tumor to inform personalized treatment decisions.
December 6, 2022
At SABCS, University of Rochester professor presents clinical trial results for Biotheranostics Breast Cancer Index
The Breast Cancer Index test is the first biomarker to be evaluated in a cohort from the Suppression of Ovarian Function Trial (SOFT), Hologic noted.
December 7, 2022
Reveal Genomics presents trial results for HER2Dx breast cancer test at SABCS
The results show that an HER2Dx risk score was significantly associated with relapse-free interval and long-term survival outcomes; additionally, HER2Dx can identify patients who might be candidates for neoadjuvants or de-escalation of systemic therapy.
December 6, 2022
Myriad Genetics to present new data at San Antonio Breast Cancer Symposium
A spotlight discussion will highlight how a combined risk score may lead to improved breast cancer prevention and screening strategies.
November 30, 2022
Halo Diagnostics, Ikonopedia partner to integrate genetic testing, breast cancer imaging software
Halo Diagnostics announced a partnership with Ikonopedia that aims to improve the detection of breast cancer by integrating genetic testing with imaging.
November 28, 2022
Netherlands study finds blood protein level changes two years prior to breast cancer diagnosis
The study found that prior to being diagnosed with breast cancer, women may experience changes in the levels of certain proteins found in the bloodstream, leading to the potential for early detection using blood tests.
November 16, 2022
Delphi Diagnostics announces use of genetic test in ongoing breast cancer trial
While the test has been used to assess tumors in the ongoing trial for the past year, it will now additionally be used for adaptive randomization of patients whose biomarker profiles show that they may benefit from endocrine therapy.
October 27, 2022
Prelude Dx to present clinical utility data for DCIS risk assessment test
DCISionRT predicts radiation therapy benefit through a risk assessment test for patients with ductal carcinoma in situ (DCIS).
October 21, 2022
Boston Cell Standards nabs FDA clearance for IHC test panel to evaluate breast cancers
Boston Cell Standards on Thursday announced that the FDA has granted 510(k) clearance for the company’s IHControls panel for evaluating breast cancers.
October 6, 2022
Roche gets FDA approval for metastatic breast cancer CDx
The Pathway anti-HER2 (4B5) test is now FDA-approved for use in the assessment of metastatic breast cancer patients who may be eligible for Enhertu, an HER2-directed antibody drug conjugate.
October 4, 2022
At-home test spots biomarkers related to breast abnormalities
Namida Lab has developed the Auria diagnostic test, which provides a personalized score and classification that corresponds to an urgency level, indicating when a mammogram should be scheduled. The laboratory-developed test is available to women between the ages of 33 and 85 with an average risk of developing breast cancer, regardless of their breast tissue density.
September 13, 2022
Page 2 of 11